Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)

AIDS

Volumn 10, Issue 9, 1996, Pages 995-999

  Schmit, Jean Claude ^a   Ruiz, Lidia ^b   Clotet, Bonaventura ^b   Raventos, Antoni ^b   Tor, Jordi ^b   Leonard, John ^c   Desmyter, Jan ^a   De Clercq, Erik ^a   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Antiviral therapy; Drug resistance; HIV 1; Molecular biology; Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0030012398     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199610090-00010     Document Type: Article

References (17)

1. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
2. Kempf DJ, Marsh KC, Denissen JF, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA, 92:2484-2488.
3. Vacca JP, Dorsey BD, Schleif WA, et al.: L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994, 91:4096-4100.
4. Ho DD, Neuman AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
5. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
6. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995, 11:671-676.
7. Mellors JW, Larder BA, Schinazi RF: Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1995, 3:8-12.
8. Markowitz M, Mo H, Kempf DL, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
9. Japour AJ, Fiscus SA, Arduino JM, et al.: Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994, 32:2291-2294.
10. Japour AJ, Mayers DL, Johnson VA, et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993, 37:1095-1101.
11. Molla A, Boucher C, Korneyeva M, et al.: Evolution of resistance to the protease inhibitor ritonavir (ABT-538) in HIV-infected patients. Fourth International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 69].
12. Danner SA, Carr A, Leonard JM, et al.: Safety, pharmacokinetics, and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
13. Markowitz M, Saag M, Powderly W, et al.: Clinical evaluation of the safety and efficacy of ritonavir (ABT 538), an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1534-1539.
14. Konvalinka J, Litterst MA, Welker R, et al.: An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J Virol 1995, 69:7180-7186.
15. Kozal MJ, Shah N, Yang R, et al.: Natural polymorphism of HIV-1 clade B protease gene and the implication for therapy. Fourth International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 76].
16. Winslow DL, Stack S, King R, Scarnati H, Bincsik A, Otto MJ: Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses 1995, 11:107-113.
17. Norbeck D, Kumar G, Marsh K, et al.: Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB-7].